CN110381970A - 包含人参果多糖的用于增强免疫力的组合物 - Google Patents
包含人参果多糖的用于增强免疫力的组合物 Download PDFInfo
- Publication number
- CN110381970A CN110381970A CN201880015262.1A CN201880015262A CN110381970A CN 110381970 A CN110381970 A CN 110381970A CN 201880015262 A CN201880015262 A CN 201880015262A CN 110381970 A CN110381970 A CN 110381970A
- Authority
- CN
- China
- Prior art keywords
- composition
- polysaccharide
- less
- acid
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 85
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 71
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 71
- 150000004676 glycans Chemical class 0.000 title claims abstract description 12
- 230000001900 immune effect Effects 0.000 title claims abstract description 8
- 241000186660 Lactobacillus Species 0.000 title claims abstract description 7
- 229940039696 lactobacillus Drugs 0.000 title claims abstract description 7
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 14
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 14
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract description 14
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims abstract description 13
- 102000013462 Interleukin-12 Human genes 0.000 claims abstract description 13
- 108010065805 Interleukin-12 Proteins 0.000 claims abstract description 13
- 239000000470 constituent Substances 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 235000002789 Panax ginseng Nutrition 0.000 claims description 21
- 240000004371 Panax ginseng Species 0.000 claims description 17
- 235000008434 ginseng Nutrition 0.000 claims description 17
- 102000004889 Interleukin-6 Human genes 0.000 claims description 13
- 235000013399 edible fruits Nutrition 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 235000019441 ethanol Nutrition 0.000 claims description 10
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 8
- 125000000188 beta-D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 8
- 239000002537 cosmetic Substances 0.000 claims description 8
- -1 galactolipin Chemical compound 0.000 claims description 8
- 238000012545 processing Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000009257 reactivity Effects 0.000 claims description 4
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 3
- 229940097043 glucuronic acid Drugs 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 claims 2
- 229940100601 interleukin-6 Drugs 0.000 claims 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims 1
- 230000036039 immunity Effects 0.000 abstract description 14
- 239000004615 ingredient Substances 0.000 abstract description 9
- 230000003014 reinforcing effect Effects 0.000 abstract description 6
- 229930014626 natural product Natural products 0.000 abstract description 5
- 150000004804 polysaccharides Chemical class 0.000 description 60
- 238000002360 preparation method Methods 0.000 description 25
- 210000002540 macrophage Anatomy 0.000 description 20
- 239000000523 sample Substances 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 235000003140 Panax quinquefolius Nutrition 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 240000005373 Panax quinquefolius Species 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000007928 intraperitoneal injection Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 239000013049 sediment Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical class [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- 238000011725 BALB/c mouse Methods 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000003147 glycosyl group Chemical group 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010985 leather Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 210000002955 secretory cell Anatomy 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229920001221 xylan Polymers 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 101710130006 Beta-glucanase Proteins 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 241000040710 Chela Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 241000222355 Trametes versicolor Species 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 235000020167 acidified milk Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 108010054251 arabinogalactan proteins Proteins 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012817 gel-diffusion technique Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229940107131 ginseng root Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012875 nonionic emulsifier Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000019449 other food additives Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Immunology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
Abstract
本说明书涉及用于增强免疫力的组合物,其包含人参果多糖作为活性成分。所述组合物可通过使用源自天然产物的成分来提高细胞因子(如IL‑6、IL‑12和TNF‑α)的表达。此外,所述组合物可由于人参果多糖的独特组分和结构而表现出优异的免疫力增强效果。
Description
技术领域
本说明书描述了用于增强免疫力的组合物,其包含人参果多糖。
背景技术
当人体免疫功能恶化时,很可能变得易受各种感染或疾病的影响。巨噬细胞是在吞噬和消除细菌或异物的过程中通过分泌多种细胞因子来调节免疫现象的细胞,并在针对抗原的免疫反应中起着关键作用。巨噬细胞参与淋巴细胞的抗原呈递和非特异性免疫应答,并表现出直接的肿瘤细胞损伤活性。此外,已知TLR(Toll样受体)反应性物质(LPS或天然产物)活化巨噬细胞并产生细胞因子,如IL-1、IL-6、IL-10、IL-12和TNF-α,它们可调节T细胞和B细胞的增殖、吞噬作用和再次免疫应答,如针对微生物感染的保护。
IL-1、IL-6和TNF-α是由巨噬细胞诱导的代表性细胞因子,已知其在细菌感染导致的炎症反应中起关键作用,并且其在炎症损伤中增加。据报道,IL-6与IL-1协同作用,参与到T细胞和B细胞的分化中。已知TNF-α具有抗病毒作用,并在多种生物反应中发挥重要作用。此外,IL-12是诱导NK细胞活化和Th1型免疫反应的细胞因子,并且已知其能够增强对细胞异物的响应。
需要源自天然产物并在这样的免疫力增强中有效的成分。
发明概述
技术问题
在一个方面中,本发明要解决的问题是提供组合物,其表现出优异的免疫力增强效果。
在另一方面中,本发明要解决的问题是提供组合物,其提高IL-6、IL-12和TNF-α的表达。
在另一方面中,本发明要解决的问题是提供组合物,其包含源自天然产物并显示出优异的免疫力增强效果的成分。
在另一方面中,本发明要解决的问题是提供组合物,其为源自天然产物并显示出很少或未显示出毒性或副作用的成分。
在另一方面中,本发明要解决的问题是提供组合物,其能够由于免疫力增强而发挥健康支持作用。
问题的解决方案
在一个方面中,本发明提供用于增强免疫力的组合物,其包含人参果多糖作为活性成分。
发明的有益效果
在一个方面中,本发明可提供组合物,其表现出优异的免疫力增强效果。
在另一方面中,本发明可提供组合物,其提高IL-6、IL-12和TNF-α的表达。
在又一方面中,本发明可提供组合物,其包含源自天然产物并显示出优异的免疫力增强效果的成分。
在再一方面中,本发明可提供组合物,其能够由于免疫力增强而发挥健康支持作用。
附图简要说明
图1示意性地说明使用β-葡萄糖基Yariv试剂检测阿拉伯半乳聚糖的反应。
图2是说明人参果中水溶性物质的流分的图。
图3是说明人参果多糖色谱分析结果的图。
图4是说明通过使用β-葡萄糖基Yariv试剂处理产生的标准物质、人参果多糖和红参根多糖的沉淀物环的照片。
图5是说明通过使用β-葡萄糖基Yariv试剂处理产生的标准物质、人参果多糖和红参根多糖的沉淀物环面积的图。
图6是说明样品在巨噬细胞中的IL-6产生能力的图。
图7是说明样品在巨噬细胞中的IL-12产生能力的图。
图8是说明样品在巨噬细胞中的TNF-α产生能力的图。
实施方式描述
在下文中,会参照附图更详细地描述本申请的实施方案。然而,本申请中公开的技术不限于本文中描述的实施方案,而是可以其他形式实施。然而,应该理解,提供本文中公开的实施方案是为了使本公开彻底且完整,并且会将本申请的范围完全传达至本领域技术人员。在附图中,组分的宽度和厚度被稍微放大,以便清楚地说明各个组分。此外,尽管为了便于解释,仅示出了一部分组分,但是本领域技术人员能够容易地掌握组分的其余部分。对于本领域技术人员而言,很明显,在不脱离本申请的精神和范围的情况下,可以对本申请进行多种修改和变化。
根据本发明的实施方案,可提供用于增强免疫力的组合物,其包含人参果多糖作为活性成分。所述人参果多糖通过其独特的组分和结构表现出调节免疫功能的作用,具体而言,所述人参果多糖表现出活化细胞因子的优异效果。因此,根据本发明实施方案的组合物可表现出非常优异的免疫力增强效果。
所述人参果多糖可为源自人参(高丽参(Panax ginseng C.A.Meyer))地上部分的浆果部分的多糖组分。在一个实例中,所述人参果可为包含人参的果肉、果皮或者果肉和果皮二者的部分。
所述人参果多糖可由将人参果使用乙醇提取后所提取的不溶性组分(在乙醇中不溶解)获得。例如,可以通过将所提取的乙醇不溶性组分用水提取来仅分离水溶性组分,并使用包含在该水溶性组分中的人参果多糖作为活性成分。例如,可以通过将所述水溶性组分浓缩、将浓缩的水溶性组分使用乙醇进行沉淀、然后移除低分子量组分来获得人参果多糖。
例如,可以通过用50%至100%的乙醇对移除种子的人参果进行提取,然后用体积为所提取的不溶性组分体积的3-10倍的水对所提取的不溶性组分进行热提取来获得水溶性提取物。将所述水溶性提取物进行浓缩,使其固体含量为10-50wt%,使用体积为所述水溶性提取物体积2-5倍的乙醇进行沉淀,并分离(使截留分子量为10000至30000),从而移除低分子量组分。所述低分子量组分的移除可通过过滤来进行,例如使用超滤膜的超滤、透析以及使用2-10倍体积的50%至100%的乙醇的溶解处理(重复1至10次)。在一个实例中,干燥可在移除低分子量组分后进行。所述干燥可以通过冷冻、热空气、喷雾或真空处理来进行。
在一个实例中,在用水提取人参果的水溶性组分之前,可进一步包括酶处理。至于酶,可以不受限制地使用任何酶,只要它是用于食品中的酶。所述酶可选自例如淀粉酶、蛋白酶、果胶酶、脂肪酶、纤维素酶、木聚糖酶、β-葡聚糖酶或支链淀粉酶。所述组合物的免疫活性可以通过酶处理来提高。所述酶处理可以通过例如所述水溶性组分与酶在40℃至60℃下反应10至60分钟来进行。
所述人参果多糖可包含阿拉伯糖、半乳糖、半乳糖醛酸和葡糖醛酸。
在一个实例中,相对于多糖的总重量,可包含在所述组合物中的半乳糖醛酸和葡糖醛酸的总含量为0.1wt%或更多、0.2wt%或更多、0.3wt%或更多、0.4wt%或更多、0.5wt%或更多、0.6wt%或更多、0.7wt%或更多、0.8wt%或更多、0.9wt%或更多、1wt%或更多、2wt%或更多、3wt%或更多、4wt%或更多、5wt%或更多、6wt%或更多、7wt%或更多、8wt%或更多、9wt%或更多或者10wt%或更多,以及25wt%或更少、24wt%或更少、23wt%或更少、22wt%或更少、21wt%或更少、20wt%或更少、19wt%或更少、18wt%或更少、17wt%或更少、16wt%或更少、15wt%或更少、14wt%或更少、13wt%或更少、12wt%或更少、11wt%或更少、10wt%或更少、9wt%或更少、8wt%或更少、7wt%或更少、6wt%或更少、5wt%或更少或者4wt%或更少。例如,所述含量可为0.1wt%至25wt%或者0.5wt%至20wt%。
相对于多糖的总重量,可包含在所述组合物中的半乳糖醛酸的含量为0.1wt%或更多、0.2wt%或更多、0.3wt%或更多、0.4wt%或更多、0.5wt%或更多、0.6wt%或更多、0.7wt%或更多、0.8wt%或更多、0.9wt%或更多、1wt%或更多、2wt%或更多、3wt%或更多、4wt%或更多、5wt%或更多、6wt%或更多、7wt%或更多、8wt%或更多、9wt%或更多或者10wt%或更多,以及20wt%或更少、19wt%或更少、18wt%或更少、17wt%或更少、16wt%或更少、15wt%或更少、14wt%或更少、13wt%或更少、12wt%或更少、11wt%或更少、10wt%或更少、9wt%或更少、8wt%或更少、7wt%或更少、6wt%或更少、5wt%或更少或者4wt%或更少。所述含量可为例如0.1wt%至20wt%、0.1wt%至15wt%、1wt%至5wt%、5wt%至15wt%或者0.5wt%至5wt%。
相对于多糖的总重量,可包含在所述组合物中的葡糖醛酸的含量为0.1wt%或更多、0.2wt%或更多、0.3wt%或更多、0.4wt%或更多、0.5wt%或更多、0.6wt%或更多、0.7wt%或更多、0.8wt%或更多、0.9wt%或更多、1wt%或更多、2wt%或更多、3wt%或更多、4wt%或更多、5wt%或更多、6wt%或更多或者7wt%或更多,以及10wt%或更少、9wt%或更少、8wt%或更少、7wt%或更少、6wt%或更少、5wt%或更少或者4wt%或更少。所述含量可为例如0.1wt%至10wt%、0.5wt%至5wt%或者0.1wt%至5wt%。
在一个实例中,相对于多糖的总重量,可包含在所述组合物中的阿拉伯糖的含量为2wt%至30wt%。
在一个实例中,相对于多糖的总重量,可包含在所述组合物中的半乳糖的含量为5wt%-50wt%。
所述人参果多糖包含高比例的阿拉伯半乳聚糖结构,因此可以表现出优异的免疫活性。所述阿拉伯半乳聚糖结构可使用β-葡萄糖基Yariv试剂检测。β-葡萄糖基Yariv试剂为(1,3,5-三-(4-β-吡喃葡萄糖基-氧基苯基偶氮)-2,4,6-三羟基苯),其特异性与阿拉伯半乳聚糖中的II型阿拉伯-β-3,6-半乳聚糖反应形成红色沉淀。阿拉伯半乳聚糖结构的浓度以浓度依赖性的方式与用β-葡萄糖基Yariv试剂处理产生的红色沉淀物环的面积成正比。当标准阿拉伯-β-3,6-半乳聚糖在相同浓度下生成的沉淀大小为100%时,人参果多糖可具有的沉淀物环面积的大小为40%或更大、50%或更大、60%或更大、70%或更大或者80%或更大,以及90%或更小、80%或更小、70%或更小或者60%或更小。沉淀面积可以为例如50%至90%或者50%至80%。
所述人参果多糖的重均分子量可以是10kDa或更高。所述人参果多糖可以具有分子量为70kDa至80kDa的主峰。所述人参果多糖在活化与免疫功能相关的细胞因子方面表现出显著优异的效果。例如,所述人参果多糖可以通过增加巨噬细胞中IL-6、IL-12和TNF-α的表达来表现出优异的免疫力增强效果。
根据本发明实施方案的组合物可以包含活性成分的食品添加剂或功能性食品的多种形式来提供。所述组合物可被加工成含有活性成分的发酵乳、奶酪、酸奶、果汁、益生菌制剂和保健食品,并可以多种其他食品添加剂的形式使用。
根据本发明实施方案的组合物可以是用于保健食品的组合物。
根据本发明实施方案的用于保健食品的组合物可包含相对于所述组合物的总重量,量为但不限于0.0001wt-99wt%,例如0.01wt-60wt%的活性成分。
在具体的实例中,用于保健食品的组合物可以被配制成丸剂、胶囊剂、片剂、颗粒剂、焦糖糖果或饮料。在另一实施方案中,所述组合物可被处理为液体、粉末、颗粒、片剂或茶包的形式。
所述组合物可通过多种方法给药,例如简单饮用、注射给药、喷雾或挤压。
所述组合物可包含在不损害本发明主要效果的范围内能够为主要效果增加协同效果的其他成分等。例如,所述组合物可以进一步包含用于改善物理性能的添加剂,例如香料、着色剂、杀菌剂、抗氧化剂、防腐剂、保湿剂、增稠剂、无机盐、乳化剂和合成聚合物材料。此外,所述组合物还可包含辅助组分,如水溶性维生素、油溶性维生素、高分子量肽、高分子量多糖和海藻提取物。本领域技术人员可以根据配方或使用目的适当选择和混合上述组分,并且其添加量可以在不损害本发明的目的和效果的范围内选择。例如,基于所述组合物的总重量,上述组分的添加量可为但不限于0.01wt%至5wt%,例如0.01wt%至3wt%。
在一实施方案中,所述组合物可以是美容组合物。
根据本发明实施方案的美容组合物可包含基于所述组合物的总重量,量为为但不限于0.0001wt-99wt%,例如0.01wt-60wt%的活性成分。
根据本发明实施方案的美容组合物可被配制成包含美容或皮肤病学上可接受的介质或基质。所述美容组合物可以混悬剂、微乳剂、微囊剂、微粒剂或离子(脂质体)和非离子囊状分散体的形式提供,或者以乳膏剂、皮肤洗剂、洗剂、散剂、软膏剂、喷雾剂或棒状遮瑕膏的形式提供,作为所有适于局部施用的制剂。所述美容组合物还可以泡沫的形式或进一步包含压缩抛射剂的气雾剂组合物的形式使用。这些组合物可以根据本领域的常规方法制备。
此外,根据本发明实施方案的美容组合物可包含通常用于美容或皮肤病学领域的辅剂,例如粉末、脂肪物质、有机溶剂、增溶剂、增稠剂、胶凝剂、软化剂、抗氧化剂、助悬剂、稳定剂、起泡剂、表面活性剂、水、离子型乳化剂或非离子型乳化剂、填充剂、多价螯合剂、螯合剂、防腐剂、维生素、阻断剂、润湿剂、精油、染料、颜料、亲水性活性剂或亲脂性活性剂、脂囊泡或美容剂中常用的任何其他成分。辅剂以美容或皮肤病学领域常用的量引入。根据本发明实施方案的美容组合物还可包含皮肤吸收促进物质以提高皮肤改善效果。
在本发明的一实施方案中,所述组合物可以是药物组合物。
根据本说明书的药物组合物可以是各种口服剂型或肠胃外剂型。在配制成制剂的情况中,使用稀释剂或赋形剂来制备制剂,所述稀释剂或赋形剂例如填充剂、增量剂、粘合剂、润湿剂、崩解剂或表面活性剂。用于口服给药的固体制剂包括片剂、丸剂、散剂药物、颗粒剂、软胶囊剂或硬胶囊剂等。这样的固体制剂通过将一种或多种化合物与至少一种或多种赋形剂(例如淀粉、碳酸钙、蔗糖或乳糖或者明胶)混合来制备。除了简单的赋形剂外,还使用例如硬脂酸镁和滑石粉的润滑剂。用于口服给药的液体制剂包括混悬剂、内服溶液剂、乳剂和糖浆剂。除常用的简单稀释剂(例如水和液体石蜡)外,液体制剂可包含多种赋形剂,例如润湿剂、甜味剂、芳香剂和防腐剂。用于肠胃外给药的制剂包括灭菌水溶液剂、非水溶液剂、混悬剂、乳剂、冷冻干燥制剂和栓剂。丙二醇、聚乙二醇、例如橄榄油的植物油、例如油酸乙酯的可注射酯等可用作非水溶剂和混悬剂的溶剂。Witepsol、聚乙二醇、吐温61、可可脂、月桂油和脂肪、甘油明胶等可用作栓剂的基质。
作为本说明书的组合物的药物剂型,所述组合物还可以这些的药学上可接受的盐的形式使用,并且所述组合物也可以单独地或与其他药学活性化合物组合以及以合适的聚集形式使用。盐没有特别限制,只要它是药学上可接受的,例如,可以使用盐酸、硫酸、硝酸、磷酸、氢氟酸、氢溴酸、甲酸、乙酸、酒石酸、乳酸、柠檬酸、富马酸、马来酸、琥珀酸、甲磺酸、苯磺酸、甲苯磺酸和萘磺酸。
本说明书的组合物可根据目的进行肠胃外给药或口服给药。所述组合物可以一次至分开的数次给药,以每天每千克体重给药0.1-500mg,优选地1-100mg的量。特定患者的剂量可以根据患者的体重、年龄、性别、健康状况、饮食、给药时间、给药方法、排泄率、疾病严重程度等而变化。
根据本说明书的药物组合物可以通过分别根据常规方法配制成适合于药物制剂的任何形式使用,包括口服剂型,例如散剂药物、颗粒剂、片剂、软胶囊剂或硬胶囊剂、混悬剂、乳剂、糖浆剂和气雾剂,用于皮肤的外用制剂,例如软膏剂和乳膏剂、栓剂、注射剂、灭菌注射液等。
根据本发明的另一实施方案,可提供用于增强免疫力的方法,其包括向需要免疫力增强的个体给药人参果多糖。所述人参果多糖与根据上述本发明实施方案的用于增强免疫力的组合物中描述的相同,因此省略了对其的描述。
根据本发明的另一个实施方案,可提供人参果多糖在制备用于增强免疫力的组合物中的用途。所述人参果多糖和用于增强免疫力的组合物与根据上述本发明实施方案的用于增强免疫力的组合物中描述的相同,因此省略了对其的描述。
实施方案
在下文中会参照实施例更详细地描述本发明。本领域技术人员会理解,这些实施例仅是对本发明的例示说明,并且本发明的范围不应解释为受这些实施例的限制。
[制备实施例1]人参果多糖的制备
将已移除种子的人参果用体积为人参果体积的10倍的90%乙醇提取,沉淀水溶性组分,并移除上清液。将所提取和沉淀的不溶性组分在90℃的温度下通过使用体积为水溶性组分体积20倍的水进行热提取5小时。将提取物浓缩以使固体含量为30wt%,将体积为浓缩物体积2倍的90%乙醇加入浓缩物中,并使浓缩物沉淀。在图2中示出针对沉淀的水溶性组分的高效液相色谱法(HPLC)的结果。通过超滤分离沉淀物以使其具有20,000的分子量截留,从而移除低分子量组分,并将分离的沉淀物冷冻干燥,以得到分子量为10kDa或更高的人参果多糖和分子量为70-80kDa的主峰。在图3中示出了由此制备的人参果多糖的高效液相色谱法(HPLC)的结果。
[制备实施例2]红参多糖的制备
除了使用红参根代替人参果,按照与制备实施例1中相同的方式制备红参多糖。
[测试实施例1]阿拉伯半乳聚糖的检测
根据Holst和Clarke(Van Holst GJ,Clarke AE.Quantification ofarabinogalactan-protein in plant extracts by single radial geldiffusion.Anal.Chem.148:446-450(1985))的方法,通过单自由基凝胶扩散测量与β-葡萄糖基Yariv试剂(Biosupplies,Parkville,澳大利亚)的反应性来确认阿拉伯-β-3,6-半乳聚糖的存在。
配制包含10μg/ml的β-葡萄糖基Yariv试剂的0.15M NaCl琼脂糖板,配置直径为2.5mm的孔,并将包含稀释至各种浓度的标准物质的阿拉伯胶的溶液和5μg样品注入各个孔中。使板在潮湿状态下静置15小时以进行反应,通过观察由此产生的红色沉淀物来观察阿拉伯-β-3,6-半乳聚糖是否存在,并通过计算所产生的沉淀物环的面积来将样品与β-葡萄糖基Yariv试剂之间的反应性进行相互比较。作为样品,以62.5、125、250、500和1000μg/ml的浓度使用标准物质,并且分别以100、500和1000μg/ml的浓度使用制备实施例1和制备实施例2中制备的多糖,如图4中所示。
测量所产生的红色沉淀物环的面积,并在图5中显示阿拉伯-β-3,6-半乳聚糖的相对含量。图5中的结果是通过比较用浓度为1000μg/ml的各样品处理的组相对于用浓度为1000μg/ml的标准物质处理的组的面积而获得的。
由图5所示的结果可以确认,人参果多糖含有高含量的阿拉伯半乳聚糖结构,其为红参多糖的2倍或更高。
[测试实施例2]对巨噬细胞中IL-6产生能力的评估
如下测量人参果多糖在巨噬细胞中的IL-6产生能力。
向BALB/c小鼠腹膜内注射1ml的5%巯基乙酸盐(thioglycollate),3天后,通过颈脱位法处死小鼠,并通过腹膜内注射10mL的DMEM培养基来收集腹膜渗出细胞(PEC)。将收集的PEC分配到96孔培养板中以获得2.0×105个细胞/孔的浓度,培养2小时以使巨噬细胞附着到板上,随后用培养基洗涤以移除未附着的细胞。将样品加入到巨噬细胞中,使得人参果纯化流分的样品溶液的终浓度为0.8μg/ml至100μg/ml,并将细胞培养72小时。培养完成后,以900rpm进行离心5分钟,以收集150μl的细胞培养基上清液,并测量培养上清液中IL-6(诱导型分泌细胞因子)的含量。结果在图6中显示。
将制备实施例1和制备实施例2的多糖用作样品,并将PSK(云芝多糖(KrestinTM),来自彩绒革盖菌(Coriolus versicolor))、由西洋参(Panax quinquefolius)根制备的CVT200(COLD-FX)和米蕈多醣体(Biobran,阿拉伯木聚糖化合物)用作阳性对照。在图6中,NC表示未处理组,并且PC表示用5μg/ml的LPS处理的组。
由图6所示的结果可见,与用作阳性对照的样品和红参多糖相比,人参果多糖显示出非常优异的IL-6产生能力。
[测试实施例3]对巨噬细胞中IL-12产生能力的评估
如下测量人参果多糖在巨噬细胞中的IL-12产生能力。
向BALB/c小鼠腹膜内注射1ml的5%巯基乙酸盐,3天后,通过颈脱位法处死小鼠,并通过腹膜内注射10mL的DMEM培养基来收集腹膜渗出细胞(PEC)。将收集的PEC分配到96孔培养板中以获得2.0×105个细胞/孔的浓度,培养2小时以将巨噬细胞附着到板上,随后用培养基洗涤以移除未附着的细胞。将样品加入到巨噬细胞中,使得人参果纯化流分的样品溶液的终浓度为0.8μg/ml至100μg/ml,并将细胞培养72小时。培养完成后,以900rpm进行离心5分钟,以收集150μl的细胞培养基上清液,并测量培养上清液中IL-12(诱导型分泌细胞因子)的含量。结果在图7中显示。
将制备实施例1和制备实施例2的多糖用作样品,并将PSK(云芝多糖,来自彩绒革盖菌)、由西洋参(Panax quinquefolius)根制备的CVT200(COLD-FX)和米蕈多醣体(阿拉伯木聚糖化合物)用作阳性对照。在图7中,NC表示未处理组,并且PC表示用5μg/ml的LPS处理的组。
由图7所示的结果可见,与用作阳性对照的样品和红参多糖相比,人参果多糖显示出非常优异的IL-12产生能力。
[测试实施例4]对巨噬细胞中TNF-α产生能力的评估
如下测量人参果多糖在巨噬细胞中的TNF-α产生能力。
向BALB/c小鼠腹膜内注射1ml的5%巯基乙酸盐,3天后,通过颈脱位法处死小鼠,并通过腹膜内注射10mL的DMEM培养基来收集腹膜渗出细胞(PEC)。将收集的PEC分配到96孔培养板中以获得2.0×105个细胞/孔的浓度,培养2小时以将巨噬细胞附着到板上,随后用培养基洗涤以移除未附着的细胞。将样品加入到巨噬细胞中,使得人参果纯化流分的样品溶液的终浓度为0.8μg/ml至100μg/ml,并将细胞培养72小时。培养完成后,以900rpm进行离心5分钟,以收集150μl的细胞培养基上清液,并测量培养上清液中TNF-α(诱导型分泌细胞因子)的含量。结果在图8中显示。
将制备实施例1和制备实施例2的多糖用作样品,并将PSK(云芝多糖,来自彩绒革盖菌)、由西洋参(Panax quinquefolius)根制备的CVT200(COLD-FX)和米蕈多醣体(阿拉伯木聚糖化合物)用作阳性对照。在图8中,NC表示未处理组,并且PC表示用5μg/ml的LPS处理的组。
由图8所示的结果可见,与用作阳性对照的样品和红参多糖相比,人参果多糖显示出非常优异的TNF-α产生能力。
[制剂实施例1]片剂
通过将100mg制备实施例1中的多糖、400mg乳糖、400mg玉米淀粉和2mg硬脂酸镁混合,然后根据制备片剂的常规方法将混合物压片来制备片剂。
[制剂实施例2]胶囊剂
通过将100mg制备实施例1中的多糖、400mg乳糖、400mg玉米淀粉和2mg硬脂酸镁混合,并根据制备胶囊剂的常规方法将混合物填充到明胶胶囊中来制备胶囊剂。
[制剂实施例3]颗粒剂
将50mg制备实施例1中的多糖、250mg无水结晶葡萄糖和550mg淀粉混合,使用流化床造粒机使混合物形成颗粒,然后将颗粒装入袋中。
[制剂实施例4]可饮用制剂
将50mg本发明制备实施例1中的多糖、10g葡萄糖、0.6g柠檬酸和25g液体寡糖混合,然后向混合物中加入300ml纯净水,并将所得的混合物装入瓶中,每瓶200ml。将装入瓶中的混合物在130℃下灭菌4至5秒,从而制备可饮用制剂。
[制剂实施例5]注射剂
通过常规方法根据下表中所示的组分制备注射剂。
[表1]
混合的成分 | 含量 |
制备实施例1中的多糖 | 10-50mg |
注射用无菌水 | 适量 |
pH调节剂 | 适量 |
Claims (11)
1.用于增强免疫力的组合物,其包含人参果多糖作为活性成分。
2.权利要求1的组合物,其中所述人参果多糖包含阿拉伯糖、半乳糖、半乳糖醛酸和葡糖醛酸。
3.权利要求2的组合物,其中相对于所述人参果多糖的总重量,其包含0.1wt%至25wt%的半乳糖醛酸和葡糖醛酸。
4.权利要求1的组合物,其中当用β-葡萄糖基Yariv试剂处理时,相对于标准阿拉伯-β-3,6-半乳聚糖的100%反应性,所述人参果多糖的反应性为40%或更高。
5.权利要求1的组合物,其中所述人参果多糖源自人参果的乙醇不溶性流分中的水溶性组分。
6.权利要求1的组合物,其中所述人参果多糖提高白介素-6(IL-6)的表达。
7.权利要求1的组合物,其中所述人参果多糖提高白介素-12(IL-12)的表达。
8.权利要求1的组合物,其中所述人参果多糖提高肿瘤坏死因子-α(TNF-α)的表达。
9.权利要求1的组合物,其中所述组合物为用于保健功能性食品的组合物。
10.权利要求1的组合物,其中所述组合物为药物组合物。
11.权利要求1的组合物,其中所述组合物为美容组合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170013005A KR102144318B1 (ko) | 2017-01-26 | 2017-01-26 | 인삼열매 다당체를 포함하는 면역 증강용 조성물 |
KR10-2017-0013005 | 2017-01-26 | ||
PCT/KR2018/001185 WO2018139898A1 (ko) | 2017-01-26 | 2018-01-26 | 인삼열매 다당체를 포함하는 면역 증강용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110381970A true CN110381970A (zh) | 2019-10-25 |
CN110381970B CN110381970B (zh) | 2023-05-12 |
Family
ID=62979125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880015262.1A Active CN110381970B (zh) | 2017-01-26 | 2018-01-26 | 包含人参果多糖的用于增强免疫力的组合物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11219653B2 (zh) |
EP (1) | EP3581192B1 (zh) |
JP (1) | JP7089524B2 (zh) |
KR (1) | KR102144318B1 (zh) |
CN (1) | CN110381970B (zh) |
WO (1) | WO2018139898A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102131043B1 (ko) | 2018-05-02 | 2020-07-08 | (주)아모레퍼시픽 | 인삼열매 다당체를 포함하는 인플루엔자 바이러스 감염 예방 또는 억제용 조성물 |
CN109160954B (zh) * | 2018-09-29 | 2020-09-08 | 上海海洋大学 | 一种香瓜茄酸性多糖及其提纯方法和用途 |
KR102163159B1 (ko) * | 2018-11-02 | 2020-10-08 | 코스맥스 주식회사 | 발효 아라비노갈락탄을 포함하는 화장료 조성물 |
KR102623444B1 (ko) * | 2019-03-14 | 2024-01-11 | (주)아모레퍼시픽 | 연질캡슐용 피막 조성물 |
KR102326439B1 (ko) | 2020-04-20 | 2021-11-16 | 주식회사 네이처센스 | 인삼을 포함하는 항균, 항염, 항바이러스 및 면역 기능 개선용 조성물 |
CN114874352B (zh) * | 2022-05-31 | 2023-01-24 | 天津中医药大学 | 一种红参hg型果胶的制备方法和结构表征方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101157731A (zh) * | 2007-11-06 | 2008-04-09 | 吉林省宏久生物科技股份有限公司 | 低农残人参、西洋参多糖提取物的制法 |
KR20130100089A (ko) * | 2013-08-27 | 2013-09-09 | 이은재 | 인삼으로부터 항암 면역증강 및 조혈촉진 효과가 있는 인삼 다당체를 정제하는 방법 및 상기 분석된 인삼 다당체를 포함하는 항암 면역증강 및 조혈촉진을 위한 조성물 |
KR101487542B1 (ko) * | 2014-06-30 | 2015-01-29 | 주식회사 헬스바이오메드 | 면역 증강용 인삼 다당체 제조방법 및 이 제조방법에 의해 제조된 면역 증강용 인삼 다당체 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9314493B2 (en) * | 2007-05-28 | 2016-04-19 | Amorepacific Corporation | Method for treating vascular inflammation, improving skin beauty and improving male sexual function using ginseng berry |
KR101382115B1 (ko) * | 2007-09-28 | 2014-04-08 | (주)아모레퍼시픽 | 인삼열매 추출물을 함유하는 아토피 피부염 개선용 식품조성물 |
KR101018989B1 (ko) * | 2007-10-31 | 2011-03-07 | 내추럴초이스 (주) | 홍삼박을 이용한 홍삼 다당체의 생산방법 |
CN101810323A (zh) * | 2009-02-23 | 2010-08-25 | 天津丹溪国药研究所 | 一种增强免疫力、抗辐射功能的保健食品 |
-
2017
- 2017-01-26 KR KR1020170013005A patent/KR102144318B1/ko active IP Right Grant
-
2018
- 2018-01-26 EP EP18745441.8A patent/EP3581192B1/en active Active
- 2018-01-26 WO PCT/KR2018/001185 patent/WO2018139898A1/ko unknown
- 2018-01-26 CN CN201880015262.1A patent/CN110381970B/zh active Active
- 2018-01-26 JP JP2019538317A patent/JP7089524B2/ja active Active
- 2018-01-26 US US16/481,295 patent/US11219653B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101157731A (zh) * | 2007-11-06 | 2008-04-09 | 吉林省宏久生物科技股份有限公司 | 低农残人参、西洋参多糖提取物的制法 |
KR20130100089A (ko) * | 2013-08-27 | 2013-09-09 | 이은재 | 인삼으로부터 항암 면역증강 및 조혈촉진 효과가 있는 인삼 다당체를 정제하는 방법 및 상기 분석된 인삼 다당체를 포함하는 항암 면역증강 및 조혈촉진을 위한 조성물 |
KR101487542B1 (ko) * | 2014-06-30 | 2015-01-29 | 주식회사 헬스바이오메드 | 면역 증강용 인삼 다당체 제조방법 및 이 제조방법에 의해 제조된 면역 증강용 인삼 다당체 |
Non-Patent Citations (5)
Title |
---|
KELLY ROSS ET AL.: "Characterization of Water Extractable Crude Polysaccharides from Cherry, Raspberry, and Ginseng Berry Fruits: Chemical Composition and Bioactivity", 《INTERNATIONAL JOURNAL OF FOOD PROPERTIES》 * |
WEI ZHANG ET AL.: "Ginseng Berry Extract Promotes Maturationof Mouse Dendritic Cells", 《PLOS ONE》 * |
YINGYU WANG ET AL.: "Extraction, characterization of a Ginseng fruits polysaccharide and itsimmune modulating activities in rats with Lewis lung carcinoma", 《CARBOHYDRATE POLYMERS》 * |
冯孟鑫: "人參果多糖的分级分离纯化及理化性质与抗肿瘤活性初探", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
刘春兰: "人参果中水溶性多糖的分离", 《中央民族大学学报( 自然科学版)》 * |
Also Published As
Publication number | Publication date |
---|---|
US11219653B2 (en) | 2022-01-11 |
EP3581192A4 (en) | 2020-09-30 |
CN110381970B (zh) | 2023-05-12 |
JP2020506683A (ja) | 2020-03-05 |
EP3581192A1 (en) | 2019-12-18 |
EP3581192B1 (en) | 2024-03-06 |
KR20180088214A (ko) | 2018-08-03 |
KR102144318B1 (ko) | 2020-08-13 |
EP3581192C0 (en) | 2024-03-06 |
US20210128660A1 (en) | 2021-05-06 |
JP7089524B2 (ja) | 2022-06-22 |
WO2018139898A1 (ko) | 2018-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110381970A (zh) | 包含人参果多糖的用于增强免疫力的组合物 | |
RU2314114C2 (ru) | Фракция геля, полученная из шелухи семян подорожника блошиного | |
KR101467903B1 (ko) | 흑미의 담자균류균사 발효 및 생물전환공정을 통해 생산된 면역증강제 | |
CN101720226B (zh) | 用于皮肤增强的芦荟制剂 | |
EP2711014A2 (en) | Daphne genkwa extracts, and pharmaceutical composition containing fractions of the extracts or compounds separated from the extracts as active ingredients for preventing or treating atopic dermatitis | |
KR20090009513A (ko) | 방사선 조사에 의한 저 분자량의 베타글루칸의 제조 방법및 방사선 조사에 의하여 제조된 저 분자량의 베타글루칸 | |
CN107205461A (zh) | 用于提高免疫机能的经酵素处理的人参源多糖组分及制备 | |
CN1777415A (zh) | 含可食用酸或其酸性盐的药物组合物及其用途 | |
JP4484014B2 (ja) | ヒアルロニダーゼ阻害、抗アレルギー活性および免疫賦活物質 | |
KR101713309B1 (ko) | 잣 껍질 추출물을 함유하는 면역증강용 식품 조성물 또는 약학 조성물 | |
JP2005068114A (ja) | タモギタケ子実体組成物及びその製造方法、並びに免疫賦活剤、抗癌剤及び食品製剤 | |
JP2002047193A (ja) | アレルギー性皮膚炎予防または治療用組成物 | |
CN112430516A (zh) | 一种抗痛风的发酵莓子酒及其制备方法 | |
CN101291679A (zh) | 包含猕猴桃属植物的组合物及其使用方法 | |
KR20200083815A (ko) | 보리 발효추출물을 이용한 알레르기성 질환의 예방, 개선 및 치료용 조성물의 제조 방법 | |
WO2023149408A1 (ja) | 化粧料組成物、表皮角化細胞増殖用化粧料組成物、表皮角化細胞増殖剤、抗酸化剤、毛乳頭細胞増殖用化粧料組成物、毛乳頭細胞増殖剤、育毛剤、ロリクリン遺伝子発現促進剤、ヘムオキシゲナーゼ-1遺伝子発現促進剤及びコーニファイドエンベロープ形成促進剤 | |
WO2022158368A1 (ja) | Gls1遺伝子阻害用化粧料組成物、gls1遺伝子阻害剤、老化細胞除去用化粧料組成物及び老化細胞除去剤 | |
KR20200096446A (ko) | 인삼열매 다당체를 포함하는 면역 증강용 조성물 | |
CN112708652B (zh) | 一种牛油果水包油液态发酵产品及其制备方法和应用 | |
KR101140683B1 (ko) | 방사선 조사에 의한 저 분자량의 베타글루칸의 제조 방법 및 방사선 조사에 의하여 제조된 저 분자량의 베타글루칸 | |
JP2005185187A (ja) | 微生物細胞壁水溶性画分及びその製造方法 | |
JP2001112438A (ja) | アガリクス茸エキスの製造方法 | |
JP7246592B2 (ja) | 自然免疫活性化剤の製造方法 | |
TWI308871B (en) | Preparation of alkali soluble polysaccharides from panax quinquefolium, process for making and use in enhancing immunity of the same | |
JP2024060257A (ja) | 抗炎症剤、TNF-α産生抑制剤、インターロイキン10産生亢進剤、皮膚外用組成物、および飲食品組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40009260 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |